[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-326838-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-326838-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","discrimination-of-pancreato-biliary-cancer-and-pancreatitis-patients-by-non-invasive-liquid-biopsy","Discrimination of pancreato-biliary cancer and pancreatitis patients by non-invasive liquid biopsy","","Current diagnostics for detecting pancreato-biliary cancers require optimization. The study proposes methylated cell-free DNA derived from non-invasive liquid biopsies as a novel biomarker to distinguish pancreato-biliary cancers from non-cancer pancreatitis patients. Differentially methylated regions from plasma cfDNA were identified using next-generation sequencing after enrichment with methyl-binding domains and database searches to build a discriminatory panel.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/discrimination-of-pancreato-biliary-cancer-and-pancreatitis-patients-by-non-invasive-liquid-biopsy/326838/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/discrimination-of-pancreato-biliary-cancer-and-pancreatitis-patients-by-non-invasive-liquid-biopsy/326838.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in diagnosing pancreato-biliary cancers?","Question",{"text":63,"@type":64},"Existing diagnostics need improved performance for detecting pancreato-biliary cancers early and reliably, especially distinguishing them from pancreatitis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the proposed biomarker approach work?",{"text":68,"@type":64},"The method uses methylated cell-free DNA from non-invasive liquid biopsies and identifies differential methylation signals to build a discriminatory biomarker panel.",{"name":70,"@type":61,"acceptedAnswer":71},"What performance did the methylation marker panel achieve?",{"text":72,"@type":64},"An unbiased machine learning approach selected 50 discriminatory methylation markers, yielding AUROC values of 0.85 for training and 0.88 for validation to distinguish pancreato-biliary cancer from pancreatitis and controls.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},326838,1790156753,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Hartwig et al. Molecular Cancer (2024) 23:28 Molecular Cancer  \n[https://doi.org/10.1186/s12943-024-01943-x](https://doi.org/10.1186/s12943-024-01943-x)  \nCORRESPONDENCE Open Access  \nDiscrimination of pancreato-biliary cancer and pancreatitis patients by non-invasive liquid biopsy  \nChristina Hartwig1,2, Jan Müller 1,3,4, Hagen Klett5, Dina Kouhestani6, Anke Mittelstädt6, Anna Anthuber6, Paul David6, Maximilian Brunner6, Anne Jacobsen6, Karolina Glanz1, Izabela Swierzy6, Lotta Roßdeutsch6, Bettina Klösch6, Robert Grützmann6,7,8,9, Timo Wittenberger5, Kai Sohn1*† and Georg F. Weber6,7,8,9*†  \nAbstract  \nBackground Current diagnostics for the detection of pancreato-biliary cancers (PBCs) need to be optimized. We therefore propose that methylated cell-free DNA (cfDNA) derived from non-invasive liquid biopsies serves as a novel biomarker with the ability to discriminate pancreato-biliary cancers from non-cancer pancreatitis patients.  \nMethods Differentially methylated regions (DMRs) from plasma cfDNA between PBCs, pancreatitis and clinical control samples conditions were identified by next-generation sequencing after enrichment using methyl-binding domains and database searches to generate a discriminatory panel for a hybridization and capture assay with subsequent targeted high throughput sequencing.  \nResults The hybridization and capture panel, covering around 74 kb in total, was applied to sequence a cohort of 25 PBCs, 25 pancreatitis patients, 25 clinical controls, and seven cases of Intraductal Papillary Mucinous Neoplasia (IPMN) . An unbiased machine learning approach identified the 50 most discriminatory methylation markers for the discrimination of PBC from pancreatitis and controls resulting in an AUROC of 0.85 and 0.88 for a training (n = 45) anda validation (n = 37) data set, respectively. The panel was also able to distinguish high grade from low grade IPMN samples.  \nConclusions We present a proof of concept for a methylation biomarker panel with better performance and improved discriminatory power than the current clinical marker CA19-9 for the discrimination of pancreato-biliary cancers from non-cancerous pancreatitis patients and clinical controls. This workflow might be used in future diagnostics for the detection of precancerous lesions, e. g. the identification of high grade IPMNs vs. low grade IPMNs.  \n†Kai Sohn and Georg F. Weber shared senior authorship and corresponding authors.  \n*Correspondence:  \nKai Sohn [Kai.Sohn@igb.fraunhofer.de](Kai.Sohn@igb.fraunhofer.de)[ ](Kai.Sohn@igb.fraunhofer.de)Georg F. Weber [Georg.Weber@uk-erlangen.de](Georg.Weber@uk-erlangen.de)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The)[. The](http://creativecommons.org/licenses/by/4.0/. The)[ ](http://creativecommons.org/licenses/by/4.0/. The)Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.","cbCaij8PX5uCk1iB","https://ap.wps.com/l/cbCaij8PX5uCk1iB","pdf",1970185,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction and clinical rationale\n## Need for optimized early diagnostics\n## Diagnostic challenge vs pancreatitis\n## Rationale for non-invasive cfDNA methylation biomarkers","[{\"question\":\"What problem does the study address in diagnosing pancreato-biliary cancers?\",\"answer\":\"Existing diagnostics need improved performance for detecting pancreato-biliary cancers early and reliably, especially distinguishing them from pancreatitis.\"},{\"question\":\"How does the proposed biomarker approach work?\",\"answer\":\"The method uses methylated cell-free DNA from non-invasive liquid biopsies and identifies differential methylation signals to build a discriminatory biomarker panel.\"},{\"question\":\"What performance did the methylation marker panel achieve?\",\"answer\":\"An unbiased machine learning approach selected 50 discriminatory methylation markers, yielding AUROC values of 0.85 for training and 0.88 for validation to distinguish pancreato-biliary cancer from pancreatitis and controls.\"}]","Discrimination of pancreato-biliary cancer and pancreatitis patients by non-invasive liquid biopsy | PDF",1789975510,18]